Is 98.4% a realistic purity ceiling for cagrilintide given its chain length?

What I am working with: 98.4% · cagrilintide.

The units are where I keep going wrong, so please be explicit about them.

I have sanity-checked the order of magnitude and it seems right, which is not the same as being right.

Is my approach right even if my number is wrong?

98.4 per cent is at the top of what stepwise synthesis delivers on a chain this long, and it is reachable rather than fictional. Every coupling is high-yielding and none is quantitative, so the deletion and truncation sequences that survive purification are what occupies the remaining 1.6 per cent. Above roughly 98 per cent you are fighting the purification rather than the synthesis, which is why a 98.4 per cent figure on cagrilintide deserves a method question — column, gradient, wavelength — rather than either belief or dismissal.

The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Reconciling gross mass to label claim

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

If you are ranking vendors, specify a method and have all samples tested at the same place.

Start from what the detector sees, because that tells you what the number means.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

In practice, sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.

edited 23 Mar 2025 by Dr_Ingrid_Baumgartner — updated for the 2026 guidance change

The underlying point is that area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

The relevant detail is that understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

edited 22 May 2025 by mz_4113 — removed a claim I could not source